Further evidence of the cardiovascular benefits of SGLT2 inhibitors in diabetes has emerged showing a protective effect of canagliflozin against heart failure, especially in patients with pre-existing disease. While CANVAS trial results from more than 10,000 patients have already shown a reduced risk of composite cardiovascular outcomes with canagliflozin (Invokana), a new analysis by Australian ...
T2D patients with heart failure get more benefit from canagliflozin: CANVAS
By Michael Woodhead
14 Mar 2018